Clinical Overview
Amoxapine is a tricyclic antidepressant with unique dopamine-blocking properties, making it structurally and pharmacologically similar to antipsychotics. It is indicated for depression, particularly in patients with psychotic features, but carries increased risk of extrapyramidal side effects and tardive dyskinesia compared to other tricyclics.
Primary Clinical Applications
Amoxapine is indicated for depression and may be particularly useful for patients with depression accompanied by psychotic features or severe agitation. Its dopamine-blocking activity provides some antipsychotic effects, making it potentially valuable for psychotic depression when combination therapy is not feasible.
Mechanism and Clinical Profile
Like other tricyclics, amoxapine blocks norepinephrine and serotonin reuptake, but it also has significant dopamine D2 receptor blocking activity. This unique profile provides antidepressant effects with some antipsychotic activity, but also increases the risk of movement disorders typically associated with antipsychotics.
Safety Considerations
Amoxapine carries a higher risk of extrapyramidal side effects and tardive dyskinesia compared to other tricyclics due to its dopamine-blocking activity. It also has the typical tricyclic risks of cardiotoxicity and anticholinergic effects, making it a less favorable choice compared to newer antidepressants for most patients.
Prescribing Information
Dosing & Administration
Depression – Adults:
- Initial: 50 mg 2-3 times daily
- Titration: May increase to 100 mg 2-3 times daily by end of first week
- Range: 200-300 mg daily in divided doses
- Maximum: 400 mg daily (outpatients), 600 mg daily (hospitalized patients)
Elderly:
- Initial: 25 mg 2-3 times daily
- Maintenance: Usually 50-150 mg daily
- Maximum: 300 mg daily
Administration:
- Divide daily dose into 2-3 administrations
- May give largest portion at bedtime if sedation is desired
- Take with food to reduce GI upset
Indications
- Treatment of depression
- May be particularly useful for depression with psychotic features
Contraindications
- Hypersensitivity to tricyclic antidepressants
- Use within 14 days of MAOI therapy
- Acute recovery period following myocardial infarction
- Concurrent use with linezolid or IV methylene blue
Warnings & Precautions
- Boxed Warning: Increased risk of suicidal thoughts and behavior in patients under 25 years
- Extrapyramidal symptoms: Higher risk than other tricyclics due to dopamine blockade
- Tardive dyskinesia: Risk with long-term use, unique among tricyclics
- Neuroleptic malignant syndrome: Rare but possible due to dopamine blockade
- Cardiovascular effects: Monitor ECG in patients with cardiac disease
- Anticholinergic effects: Dry mouth, constipation, urinary retention
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CNS depressants: Enhanced sedation
- Anticholinergic drugs: Additive anticholinergic effects
- CYP2D6 inhibitors: Increase amoxapine levels
- Dopaminergic drugs: Antagonized by amoxapine’s dopamine blockade
Adverse Reactions
Common:
- Drowsiness, dry mouth, constipation, blurred vision
- Dizziness, tremor, confusion
Unique to amoxapine:
- Extrapyramidal symptoms (akathisia, dystonia, parkinsonism)
- Tardive dyskinesia with chronic use
Serious:
- Cardiac arrhythmias, seizures, neuroleptic malignant syndrome
Special Populations
- Elderly: Higher risk of anticholinergic and extrapyramidal effects
- Cardiac Disease: Requires careful monitoring due to cardiotoxic potential
- Pregnancy: Category C – use only if benefits outweigh risks
- Movement disorder risk: Monitor for extrapyramidal symptoms and tardive dyskinesia
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
